Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Researchers retract multisensory learning paper after failed replications
Even though one set of experiments did not hold up, the authors stand by the original conclusions of the work and plan to resubmit it as a new paper.
Researchers retract multisensory learning paper after failed replications
Even though one set of experiments did not hold up, the authors stand by the original conclusions of the work and plan to resubmit it as a new paper.
Cortical evolution, ZBTB18, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 30 March.
Cortical evolution, ZBTB18, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 30 March.
Letter asks Congress for nearly $500 million to sustain BRAIN Initiative
The one-time boost would help counter the planned end this year to one of the program’s long-standing funding streams, which will result in a $195 million drop in funding for fiscal year 2027.
Letter asks Congress for nearly $500 million to sustain BRAIN Initiative
The one-time boost would help counter the planned end this year to one of the program’s long-standing funding streams, which will result in a $195 million drop in funding for fiscal year 2027.